LRMR
Companies
NASDAQ
Larimar Therapeutics Inc.
Health Care
$2.60
-$1.27 (-32.82%)
Price Chart
Overview
About LRMR
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Market Cap
$611.9M
Volume
3.4M
Avg. Volume
3.4M
P/E Ratio
-1.3376623
Dividend Yield
0.00%
Employees
39.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.18
Moderate Correlation
Volatility
High (0.83)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, LRMR shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025